| Autor: |
Rafael H. Isaac, Deyanira Gonzalez-Devia, Carlos O. Mendivil, Edgardo Chapman |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Allergy, Vol 4 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2673-6101 |
| DOI: |
10.3389/falgy.2023.1201807 |
| Popis: |
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder that causes extremely elevated plasma triglyceride levels, with limited therapeutic options. Volanesorsen is an antisense oligonucleotide approved for its treatment. A 24-year-old woman with genetically diagnosed FCS secondary to a pathogenic variant in APOA5 and a history of recurrent hypertriglyceridemia-induced pancreatitis episodes was being treated with volanesorsen, 285 mg every 2 weeks. Treatment with volanesorsen achieved normalization of triglycerides to |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
